1. Home
  2. GSIT vs BMEA Comparison

GSIT vs BMEA Comparison

Compare GSIT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSIT
  • BMEA
  • Stock Information
  • Founded
  • GSIT 1995
  • BMEA 2017
  • Country
  • GSIT United States
  • BMEA United States
  • Employees
  • GSIT N/A
  • BMEA N/A
  • Industry
  • GSIT Semiconductors
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSIT Technology
  • BMEA Health Care
  • Exchange
  • GSIT Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • GSIT 98.7M
  • BMEA 114.3M
  • IPO Year
  • GSIT N/A
  • BMEA 2021
  • Fundamental
  • Price
  • GSIT $2.93
  • BMEA $1.92
  • Analyst Decision
  • GSIT
  • BMEA Strong Buy
  • Analyst Count
  • GSIT 0
  • BMEA 11
  • Target Price
  • GSIT N/A
  • BMEA $16.55
  • AVG Volume (30 Days)
  • GSIT 237.3K
  • BMEA 586.1K
  • Earning Date
  • GSIT 10-23-2025
  • BMEA 10-28-2025
  • Dividend Yield
  • GSIT N/A
  • BMEA N/A
  • EPS Growth
  • GSIT N/A
  • BMEA N/A
  • EPS
  • GSIT N/A
  • BMEA N/A
  • Revenue
  • GSIT $22,130,000.00
  • BMEA N/A
  • Revenue This Year
  • GSIT N/A
  • BMEA N/A
  • Revenue Next Year
  • GSIT N/A
  • BMEA N/A
  • P/E Ratio
  • GSIT N/A
  • BMEA N/A
  • Revenue Growth
  • GSIT 6.14
  • BMEA N/A
  • 52 Week Low
  • GSIT $1.62
  • BMEA $1.29
  • 52 Week High
  • GSIT $5.89
  • BMEA $13.07
  • Technical
  • Relative Strength Index (RSI)
  • GSIT 35.27
  • BMEA 56.71
  • Support Level
  • GSIT $2.82
  • BMEA $1.79
  • Resistance Level
  • GSIT $3.24
  • BMEA $2.08
  • Average True Range (ATR)
  • GSIT 0.16
  • BMEA 0.11
  • MACD
  • GSIT 0.02
  • BMEA 0.02
  • Stochastic Oscillator
  • GSIT 20.37
  • BMEA 58.97

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: